TELO
Income statement / Annual
Last year (2023), Telomir Pharmaceuticals, Inc. Common Stock's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Telomir Pharmaceuticals, Inc. Common Stock's net income was -$13.07 M.
See Telomir Pharmaceuticals, Inc. Common Stock,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$3.94 M |
$0.00 |
$0.00 |
| Gross Profit |
-$3.94 M |
$0.00 |
$0.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
| Research and Development
Expenses |
$1.57 M
|
$833,206.00
|
$126,492.00
|
| General & Administrative
Expenses |
$600,192.00
|
$20,941.00
|
$11,639.00
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$600,192.00
|
$20,941.00
|
$11,639.00
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$3.94 M |
$854,147.00 |
$138,131.00 |
| Cost And Expenses |
$3.94 M |
$854,147.00 |
$138,131.00 |
| Interest Income |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$1.64 M |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
-$7.49 M
|
$854,147.00
|
$138,131.00
|
| EBITDA |
-$11.43 M
|
-$854,147.00
|
-$138,131.00
|
| EBITDA Ratio |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
-$9.13 M
|
$0.00
|
$0.00
|
| Income Before Tax |
-$13.07 M |
-$854,147.00 |
-$138,131.00 |
| Income Before Tax Ratio
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00 |
-$854,144.00 |
-$138,132.00 |
| Net Income |
-$13.07 M |
-$854,147.00 |
-$138,131.00 |
| Net Income Ratio |
0 |
0 |
0 |
| EPS |
-0.44 |
-0.0288 |
-0.0047 |
| EPS Diluted |
-0.44 |
-0.0288 |
-0.0047 |
| Weighted Average Shares
Out |
$29.61 M
|
$29.61 M
|
$29.61 M
|
| Weighted Average Shares
Out Diluted |
$29.61 M
|
$29.61 M
|
$29.61 M
|
| Link |
|
|
|
